Leiden University Scholarly Publications

Persistent URL of this record https://hdl.handle.net/1887/3181182

In Collections

This item can be found in the following collections:

Groeneveldt, C.; Hall, T. van; Burg, S.H. van der; Dijke, P. ten; Montfoort, N. van (2020)

Immunotherapeutic Potential of TGF-beta Inhibition and Oncolytic Viruses

Article / Letter to editor
In cancer immunotherapy, a patient's own immune system is harnessed against cancer. Immune checkpoint inhibitors release the brakes on tumor-reactive T cells and, therefore, are particularly effective in treating certain immune-infiltrated solid tumors. By contrast, solid tumors with immune-silent profiles show limited efficacy of checkpoint blockers due to several barriers. Recent discoveries highlight transforming growth factor-beta (TGF-beta)-induced immune exclusion and a lack of immunogenicity as examples of these barriers. In this review, we summarize preclinical and clinical evidence that illustrates how the inhibition of TGF-beta signaling and the use of oncolytic viruses (OVs) can increase the efficacy of immunotherapy, and discuss the promise and challenges of combining these approaches with immune checkpoint blockade.
All authors
Groeneveldt, C.; Hall, T. van; Burg, S.H. van der; Dijke, P. ten; Montfoort, N. van
Date
2020-05-01
Journal
Trends in Immunology
Volume
41
Issue
5
Pages
406 - 420
DOI
doi:10.1016/j.it.2020.03.003